Search Results
10
Everything
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
March 24, 2025 05:00 ET
|
AKAMPION
Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-upSuccessful vascularization and vessel formation in two-year follow-up...
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025 04:00 ET
|
AKAMPION
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
October 09, 2024 04:00 ET
|
AKAMPION
Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as highSafety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being ...
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
June 05, 2024 04:00 ET
|
AKAMPION
Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in AustraliaAI-driven, no-touch manufacturing to ensure highest...
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
April 03, 2024 04:00 ET
|
AKAMPION
Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
March 05, 2024 04:00 ET
|
AKAMPION
-- Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet -- Graft vascularization was achieved by embedding vascular pedicle into the scaffold ...
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
January 31, 2024 04:00 ET
|
AKAMPION
New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
September 05, 2023 04:00 ET
|
AKAMPION
Key milestone for novel, resorbable breast / pectus reconstruction implants Leipzig, Germany, September 5, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
July 06, 2023 04:00 ET
|
AKAMPION
Market entry under new EU regulations for medical devicesSpearheading the commercialization of 3D-printed regenerative medicine products Leipzig, Germany, July 6, 2023 – BellaSeno GmbH, an ISO...
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
May 09, 2023 03:30 ET
|
AKAMPION
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...